NAPLES, Fla., May 18, 2021 — Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid (CBD) medicines to improve quality of life for cancer patients,…
Read More
Cedars-Sinai Veteran Physician Joins Four Additional Clinical, Oncology and Cannabinoid Experts to Guide the Company’s Research and Scientific Programs NAPLES, Fla., May 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a…
Read More
NAPLES, FL / April 14, 2021 / Enveric Biosciences (NASDAQ:ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today…
Read More
https://www.cancernetwork.com/view/oncology-peer-review-on-the-go-1-on-1-with-david-johnson-enveric-s-endocannabinoid-products-for-glioblastoma
Read More
https://fortune.com/2021/04/13/happy-employees-happy-shareholders/
Read More
NAPLES, Fla., April 12, 2021 — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that…
Read More
https://www.youtube.com/watch?v=MbjU8voufmg
Read More
Strengthened balance sheet during the first quarter of 2021 with the closing of two direct offerings totaling $22.8 million in gross proceeds and $3.3 million from the exercise of warrants…
Read More
https://www.benzinga.com/markets/penny-stocks/21/03/20317890/enverics-patient-centric-model-to-enhance-the-quality-of-life-of-cancer-patients
Read More
